Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and improving
-
order to gain novel understanding of the molecular mechanisms underlying disease. About You You will have a PhD (or equivalent qualification) in computer/statistics/data science or similar field. You will
-
delivers measurable value. You will lead a high-performing team to build advanced analytics capabilities, including propensity modeling, marketing mix modeling (MMM), incrementality testing, and multi-touch
-
degree, who hold an ACVECC Diploma. A background in research work in one of the College’s areas of special interest or hold a PhD, although desirable, are not essential. We offer a generous reward package
-
migration and in vivo murine models of inflammation and technical expertise in complex flow cytometry is essential. The previous ability to work with rodents would be advantageous, whilst experience in
-
this important project, the main duty of this post will be to develop, design and validate a Transfusion Platform that will allow for the data linkage between different electronic databases at Barts Health
-
PhD (or close to completion) or research qualification/experience equivalent to PhD level in the relevant subject area for the research programme; with a productive track record and have experience
-
funded by UK Research and Innovation (UKRI), this programme is part of the government’s strategic effort to position the UK at the forefront of global AI expertise. Our goal is to train PhD researchers
-
the successful candidate for this position. Therefore, the appointable candidate will need to be eligible to work in the UK or have leave to remain in the UK and associated right to work for the duration
-
– a £43.6M national programme co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing